//AstraZeneca’s absurd and unprecedented dispute with regulators, explained

AstraZeneca’s absurd and unprecedented dispute with regulators, explained

The Covid-19 vaccine developed by the University of Oxford and AstraZeneca was found to have 76 percent efficacy against disease in the US. The company was criticized by the NIH for how it presented its results this week. | Nicolas Armer/DPA/Picture Alliance via Getty Images

The company said its Covid-19 vaccine developed with Oxford had 76 percent efficacy in the US after a rare public rebuke from the NIH.

AstraZeneca announced on Thursday that the Covid-19 vaccine it developed with the University of Oxford had 76 percent efficacy against Covid-19 cases that produce symptoms, based on an analysis of its US phase 3 clinical trial.

The data release comes after a remarkable public rebuke from the National Institutes of Health for how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

On Monday, AstraZeneca announced in